New PET tracer could reveal hidden breast cancer activity
NCT ID NCT03083288
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase study tests a new PET imaging agent called 18F-FluorThanatrace (FTT) to measure a protein called PARP-1 in breast cancer tumors. About 30 adults with known or suspected breast cancer will receive an FTT PET/CT scan before surgery or treatment. Some may get a second scan after starting therapy to see how the tumor responds. The goal is to learn whether this scan can help doctors better see and monitor breast cancer, not to treat it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.